Home » Blog » Report Says Nearly 50% of Phase II & III Trial Sites Miss Enrollment Targets

Report Says Nearly 50% of Phase II & III Trial Sites Miss Enrollment Targets

IP Blog | Dave Melin | January 31, 2016

BioBlog Weekly oncologyThis week in healthcare: ASCO releases a policy statement with recommendations for clinical pathways in oncology and a recent poll at the Tufts Center for the Study of Drug Development reports nearly 50% of phase II and III trial sites missed enrollment targets.

American Society of Clinical Oncology Policy Statement on Clinical Pathways in Oncology

In response to concerns about “the process being used for pathway development, the administrative burdens on oncology practices of reporting on pathway adherence, and understanding the true impact of pathway use on patient health outcomes,” ASCO has developed and released a policy statement summarizing their stance and recommendations to address these concerns.

Tufts Report: Biopharma Heeding Call to Improve Drug Trial Performance

Following a recent poll at the Tufts Center for the Study of Drug Development Executive Forum that showed “48 percent of their phase II and III trial sites missed enrollment targets in 2015 and 11 percent failed to recruit a single patient”, many in the biopharma realm are working to improve their drug trial performance.

AmerisourceBergen Launches Innovation Center to Support Independent Oncology

In a recent press release, AmerisourceBergen announced the launch of Innovation Cancer, “a community of independent oncologists from across the nation that utilizes business intelligence tools and other resources that enable their practices to focus on providing the highest quality of care” that will offer “access to business coaching and technology designed to improve practice efficiency, as well as marketing capabilities to help make patients more aware of their choices in where to receive treatment.”

Looking for a Hep C Price War? Merck Just Started It.

Amid much discussion of national rising drug costs, Merck has announced a 42% discount on its Hep C drug Harvoni, citing that its price is “in the range of net prices” of its competitors.

Paying Providers for Value: The Path Forward

This article digs into the Health Care Payment Learning and Action Network’s recently released Alternative Payment Model (APM) Framework White Paper, which is meant to “ establish a common framework and a set of conventions to facilitate discussions among stakeholders and expedite the generation of evidence-based knowledge about the capabilities and outcomes of APMs.”

Groundbreaking Collaborative Breast Cancer Study Aims to Unlock the Doors of Individualized Patient Care with Big Data

A massive collaborative breast cancer study that brought together more than 30 researchers is attempting to “identify potential interventions for a patient with metastatic triple-negative breast cancer (TNBC)—an especially aggressive subset of breast cancer that is widely considered to be incurable” — all with the use of big data sharing on the cloud.

Obama Creates New Cancer Task Force, Blessing Biden’s Efforts

After announcing support for VP Joe Biden’s “cancer moonshot” initiative, President Obama has created a new federal cancer task force whose goal is “to double the rate of progress on treatment and prevention.”

Some Millionaires Qualify for Health Plan Subsidies under the ACA

Since a provision of the ACA bases its subsidy calculation on income, as opposed to net worth, apparently “some millionaires are obtaining financial aid for their health plans.”

Want more health care landscape updates and insights? Follow us on Twitter @innovpartners.

Topics in this Post:

Leave a Comment

Your email address will not be published. Required fields are marked *